EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis

Jens Ingvarsson iD, Viktor Grut iD, Martin Biström iD, Linn Persson Berg, Julia Butt, Birgitta Michels, Pernilla Stridh, Tomas Olsson, Lars Alfredsson, Ingrid Kockum iD, Tim Waterboer, Staffan Nilsson und 1 weitere

Clinical & Translational Immunology · 2026-04 · 15 (4)

DOI: 10.1002/cti2.70094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 16.04.2026. Verfasst von Jens Ingvarsson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Neurosciences Umeå University Umeå Sweden. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Region Jämtland Härjedalen, Swedish Foundation for MS Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein–Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV‐6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association.

Methods

Bio‐banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum‐neurofilament light chain (S‐NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI).

Results

Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV‐6A serostatus (OR = 1.67, 95% CI 1.29–2.14, P < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S‐NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group‐level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07–2.98, P = 0.028).

Conclusions

Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.

Schlagwörter

Stichwörter der Autor:innen

multiple sclerosisneurofilament light‐chainrubella virusserologyvaccination

Autor:innen und Institutionen

  • Department of Clinical Sciences, Neurosciences Umeå University Umeå Sweden.
  • Department of Infectious Diseases, Institute of Biomedicine University of Gothenburg Gothenburg Sweden.
  • Department of Clinical Microbiology Sahlgrenska University Hospital Gothenburg Sweden.
  • Division of Infections and Cancer Epidemiology German Cancer Research Center Heidelberg Germany.
  • Department of Clinical Neuroscience Karolinska Institutet Stockholm Sweden.
  • Center for Molecular Medicine Karolinska University Hospital Stockholm Sweden.

ORCID-Profile: Jens Ingvarsson, Viktor Grut, Martin Biström, Ingrid Kockum, Peter Sundström

Förderung

  • Vetenskapsrådet
  • Region Jämtland Härjedalen
  • Swedish Foundation for MS Research
  • Deutsche Forschungsgemeinschaft
  • Hjärnfonden

Zitieren

APA

Ingvarsson, J., Grut, V., Biström, M., Berg, L. P., Butt, J., Michels, B., Stridh, P., Olsson, T., Alfredsson, L., Kockum, I., Waterboer, T., Nilsson, S., & Sundström, P. (2026). Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis. Clinical & Translational Immunology, 15(4). https://doi.org/10.1002/cti2.70094

Vancouver

Ingvarsson J, Grut V, Biström M, Berg LP, Butt J, Michels B, et al. Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis. Clinical & Translational Immunology. 2026;15(4). doi:10.1002/cti2.70094

BibTeX
@article{Ingvarsson2026,
  author = {Ingvarsson, Jens and Grut, Viktor and Biström, Martin and Berg, Linn Persson and Butt, Julia and Michels, Birgitta and Stridh, Pernilla and Olsson, Tomas and Alfredsson, Lars and Kockum, Ingrid and Waterboer, Tim and Nilsson, Staffan and Sundström, Peter},
  title = {Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {4},
  doi = {10.1002/cti2.70094}
}
Kostenlos starten →